@article{bd44ef40b2014fee8b7abdd98924ac02,
title = "Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care",
keywords = "3122 Cancers, 3126 Surgery, anesthesiology, intensive care, radiology, androgen deprivation therapy, castration, cost, hormones, leuprorelin, practical differences, prostate cancer, testosterone, ANDROGEN-DEPRIVATION THERAPY, INNOVATIVE PHARMACEUTICAL FORMS, LEUPROLIDE ACETATE, TESTOSTERONE LEVELS, LEUPRORELIN ACETATE, DEPOT FORMULATIONS, OPEN-LABEL, PHASE-III, 20 NG/DL",
author = "Davide Meani and Mladen Solari{\'c} and Harri Visap{\"a}{\"a} and Rose-Marie Ros{\'e}n and Robert Janknegt and Majana So{\v c}e",
year = "2018",
month = feb,
day = "1",
doi = "10.1177/1756287217738985",
language = "English",
volume = "10",
pages = "51--63",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Inc.",
number = "2",
}